The specialist warning includes a dose boundary
The author of the 2025 AGS/AAO position statement advises against nicotinamide at 3 grams per day or more outside monitored clinical trials. Even lower amounts require coordination with the treating physician and liver-function monitoring; below 3 grams does not mean established safety. [1]
B3 products are not interchangeable
Nicotinamide and nicotinic acid are different forms within the B3 category. Do not substitute a niacin cholesterol product for a nicotinamide research preparation. Ordinary nutritional requirements are also not the same question as a proposed pharmacological regimen for an eye disease. [2][1]
Keep established glaucoma treatment in place
NEI describes medicines, usually eye drops, laser treatment and surgery as treatment options. Glaucoma may progress without noticeable early symptoms. Supplement use does not replace scheduled examinations or the treatment selected to protect vision. [3]
Liver history and symptoms matter
The position-statement author advises against potential nicotinamide therapy in people with current or past liver dysfunction. Nausea, vomiting or yellowing of skin or eyes during use should be reported promptly, with emergency evaluation when severe. [1]
Convert the units without converting them into advice
Imagine a research description mentions 3 grams and a bottle supplies 500 mg per capsule. Three grams equals 3,000 mg, or six such capsules. That calculation explains why research exposure can be substantial; it is not an instruction to take six capsules. [1]
| Situation | Response |
|---|---|
| 3 g equals 3,000 mg | Research boundary, not a home regimen |
| Lower than 3 g | Still needs clinical oversight |
| B3 product switch | Forms are not interchangeable |

Sources for this article
- Investigating Nicotinamide and Pyruvate for Glaucoma Neuroprotection
Source consulted: 2026-09-20. This is a reference resource, not a claim that we conducted the studies or tested a product. - Niacin - Health Professional Fact Sheet
Source consulted: 2026-09-20. This is a reference resource, not a claim that we conducted the studies or tested a product. - Glaucoma
Source consulted: 2026-09-20. This is a reference resource, not a claim that we conducted the studies or tested a product.